Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based private equity firm Riverside Partners in collaboration with BioAgilytix founders and management team has completed investing in the contract bioanalytical laboratory, BioAgilytix Labs.
Subscribe to our email newsletter
Offering outsourced laboratory services like analysis of biological samples, BioAgilytix serves the pharmaceutical, biotechnology, and agriculture industries which support drug discovery, pre-clinical and clinical development, and manufacturing.
BioAgilytix co-founder and CEO Jim Petrilla said, "The Riverside team has a great understanding of how to scale a pharmaceutical services business, and the two organizations have a very strong cultural fit."
Riverside Partners general partner Philip Borden added, "Co-Founders Jim Petrilla and Dr. Afshin Safavi have built a terrific business focused on supporting large molecule drug development, a very exciting area within the pharmaceutical and biotechnology industries."
The company manages $1bn of equity capital and seeks to make investments in companies with revenues between $20m and $200m and with $5-$25m of EBITDA.